|
|||||
|
|
The roles of apo(a) size,phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab |
|
| Affiliation: | 2. Public Health Sciences, University of California, Davis, CA;4. Department of Statistics and Actuarial Science, University of Hong Kong, Pokfulam, Hong Kong |
| Abstract: | |
| Keywords: | lipoprotein (a) apolipoprotein (a) apolipoproteins clinical studies lipoproteins drug therapy/hypolipidemic drugs familial hypercholesterolemia hypercholesterolemic monoclonal antibody low density lipoprotein cholesterol reduction genetic variability proprotein convertase subtilisin/kexin type 9 |
| 本文献已被 ScienceDirect 等数据库收录！ | |